Related Experiment Video

Updated: May 14, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Triptolide Transcriptionally Represses HER2 in Ovarian Cancer Cells by Targeting NF-κB

Chien-Chih Ou1, Yuan-Wu Chen, Shih-Chung Hsu

  • 1Department of Obstetrics and Gynecology, Tri-Service General Hospital, No. 325, Section 2, Cheng-Kung Road, Neihu, Taipei 11490, Taiwan.

Evidence-Based Complementary and Alternative Medicine : Ecam
|January 25, 2013
PubMed

Insights

Triptolide (TPL) effectively inhibits cancer cell proliferation by downregulating HER2 protein expression and suppressing the PI3K/Akt pathway. This study reveals TPL

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Triptolide (TPL) shows promise as an anticancer agent by inhibiting cancer cell proliferation.
  • HER2 overexpression is implicated in various cancers, making it a therapeutic target.

Purpose of the Study:

  • To investigate the mechanism by which TPL affects HER2 expression and downstream signaling pathways.
  • To evaluate the therapeutic potential of TPL in preclinical cancer models.

Main Methods:

  • Assessing TPL's effect on HER2 protein and promoter activity in oral, ovarian, and breast cancer cells.
  • Investigating the role of Nuclear Factor-kappa B (NF-κB) in TPL's action.
  • Analyzing the impact of TPL on phosphorylated HER2, PI3K, and Akt.
  • Evaluating tumor growth inhibition and protein expression in a mouse xenograft model using immunohistochemistry (IHC).

Main Results:

  • TPL dose- and time-dependently downregulates HER2 protein expression and promoter activity.
  • NF-κB is identified as a key mediator in TPL's suppression of HER2.
  • TPL inhibits activated HER2, PI3K, and Akt signaling.
  • TPL treatment reduces tumor growth and HER2/Ki-67 expression in vivo.

Conclusions:

  • TPL exerts its anticancer effects by transrepressing HER2 and inhibiting the PI3K/Akt pathway.
  • TPL demonstrates significant potential as a chemotherapeutic agent for HER2-related cancers.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Repressible Operon: trp Operon01:21

Repressible Operon: trp Operon

The trp operon in Escherichia coli exemplifies a repressible operon. It regulates the synthesis of tryptophan through repressor-mediated transcriptional control and attenuation. This dual regulatory mechanism ensures tryptophan biosynthesis occurs only when needed, conserving cellular resources.Structure of the trp OperonThe trp operon consists of five structural genes (trpE, trpD, trpC, trpB, and trpA) that encode enzymes for tryptophan biosynthesis. These genes are transcribed as a single...
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a DNA...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...